Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Therapeutic Duplication as a Medication Error Risk in Fixed-Dose Combination Drugs for Dyslipidemia: A Nationwide Study

  • Received : 2023.06.26
  • Accepted : 2023.09.11
  • Published : 2023.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background & Objectives: Fixed-dose combinations (FDCs) offer advantages in adherence and cost-effectiveness compared to free combinations (FCs), but they can also complicate the prescribing process, potentially leading to therapeutic duplication (TD). This study aimed to identify the prescribing patterns of FDCs for dyslipidemia and investigate their associated risk of TD. Methods: This was a retrospective cohort study involving drugs that included statins, using Health Insurance Review & Assessment Service-National Patient Sample (HIRA-NPS) data from 2018. The unit of analysis was a prescription claim. The primary outcome was TD. The risk ratio of TD was calculated and adjusted for patient, prescriber, and the number of cardiovascular drugs prescribed using a multivariable Poisson model. Results: Our study included 252,797 FDC prescriptions and 515,666 FC prescriptions. Of the FDC group, 46.52% were male patients and 56.21% were aged 41 to 65. Ezetimibe was included in 71.61% of the FDC group, but only 0.25% of the FC group. TD occurred in 0.18% of the FDC group, and the adjusted risk ratio of TD in FDC prescriptions compared to FC was 6. 44 (95% CI 5. 30-7. 82). Conclusions: Prescribing FDCs for dyslipidemia was associated with a higher risk of TD compared to free combinations. Despite the relatively low absolute prevalence of TD, the findings underline the necessity for strategies to mitigate this risk when prescribing FDCs for dyslipidemia. Our study suggests the potential utility of Clinical Decision Support Systems and standardizing nomenclature in reducing medication errors, providing valuable insights for clinical practice and future research.

Keywords

Acknowledgement

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2021R1A6A1A03044296).

References

  1. Committee of Clinical Practice Guideline. Korean guidelines for the management of dyslipidemia. 5th ed. Seoul, Korea: The Korean Society of Lipid and Atherosclerosis, 2022.
  2. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation 2019;140(11):e596-e646. https://doi.org/10.1161/CIR.0000000000000725
  3. Cho SMJ, Lee H, Lee H-H, et al. Dyslipidemia fact sheets in Korea 2020: An analysis of nationwide population-based data. J Lipid Atheroscler 2021;10(2):202-9. https://doi.org/10.12997/jla.2021.10.2.202
  4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The task force for the management of dyslipidaemias of the european society of cardiology (ESC) and european atherosclerosis society (EAS). Eur Heart J 2019;41(1):111-88. https://doi.org/10.1093/eurheartj/ehz455
  5. World report on ageing and health. Geneva: World Health Organization, 2015.
  6. Kim TE, Lee RG, Park SY, Oh IH. Measuring trends in the socioeconomic burden of disease in Korea, 2007-2015. J Prev Med Public Health 2022;55(1):19-27. https://doi.org/10.3961/jpmph.21.594
  7. Primary medical chronic disease management pilot project guide (translated title). 3rd ed. Sejong, Korea: Ministry of Health and Welfare, 2021.
  8. Adherence to long-term therapies: Evidence for action. Geneva, Switzerland: World Health Organization, 2003.
  9. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med 2007;120(8):713-9. https://doi.org/10.1016/j.amjmed.2006.08.033
  10. Chung S, Ko Y-G, Kim JS, et al. Effect of fixed-dose combination of ARB and statin on adherence and risk factor control: The randomized FIXAR study. Cardiol J 2022;29(5):815-23. https://doi.org/10.5603/CJ.a2020.0167
  11. Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence: Results from the focus project. J Am Coll Cardiol 2014;64(20):2071-82. https://doi.org/10.1016/j.jacc.2014.08.021
  12. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Affairs 2011;30(1):91-9. https://doi.org/10.1377/hlthaff.2009.1087
  13. Poulter NR, Borghi C, Parati G, et al. Medication adherence in hypertension. Journal of Hypertension 2020;38(4):579-87. https://doi.org/10.1097/HJH.0000000000002294
  14. Moriarty F, Bennett K, Fahey T. Fixed-dose combination antihypertensives and risk of medication errors. Heart 2019;105(3):204-9. https://doi.org/10.1136/heartjnl-2018-313492
  15. Yang S-Y, Jang S, Kwon S, et al. Effectiveness of the pilot project for polypharmacy management (translated title). Health and Social Welfare Review 2020;40(3):563-91.
  16. Koo H, Lee JW, Choi HE, Je NK, Jeong KH. Class duplication prescriptions in patients taking fixed-dose combination antihypertensives (translated title). Korean J Clin Pharm 2022;32(2):125-32. https://doi.org/10.24304/kjcp.2022.32.1.125
  17. National health insurance reimbursement medicine list (translated title). Sejong, Korea: Ministy of Health and Welfare, 2018.
  18. Kim L, Kim J-A, Kim S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health 2014;36:e2014008.
  19. Drug utilization review. Wonju, Korea: Health Insurance Review & Assessment Service; 2013 . Available from: https://www.hira.or.kr/eng/news/01/__icsFiles/afieldfile/2013/10/15/brochure_6.DUR.pdf. Accessed September 11, 2023.
  20. Jung SY, Jang EJ, Choi S, et al. Effect of a nationwide real-time drug utilization review system on duplicated nonsteroidal antiinflammatory drug prescriptions in Korea. Arthritis Care Res (Hoboken) 2020;72(10):1374-82. https://doi.org/10.1002/acr.24054
  21. Therapeutic duplicate medication product list December 1, 2018 (translated title). Wonju, Korea: Health Insurance and Assessment Service, 2018.
  22. Notice on DUR review of therapeutic duplication for combination medicines and information on discontinued production, import, and supply of medicines (translated title). Wonju, Korea: Health Insurance Review & Assessment Service, 2020.
  23. Velo GP, Minuz P. Medication errors: Prescribing faults and prescription errors. Br J Clin Pharmacol 2009;67(6):624-8. https://doi.org/10.1111/j.1365-2125.2009.03425.x
  24. Institute of Medicine (US) Committee on Quality of Health Care in America. To err is human: Building a safer health system. Washington (DC): National Academies Press (US), 2000.
  25. Tully MP, Ashcroft DM, Dornan T, Lewis PJ, Taylor D, Wass V. The causes of and factors associated with prescribing errors in hospital inpatients. Drug Saf 2009;32(10):819-36. https://doi.org/10.2165/11316560-000000000-00000
  26. Lambert BL, Chang K-Y, Lin S-J. Effect of orthographic and phonological similarity on false recognition of drug names. Soc Sci Med 2001;52(12):1843-57. https://doi.org/10.1016/S0277-9536(00)00301-4
  27. Lambert BL, Lin S-J, Tan H. Designing safe drug names. Drug Saf 2005;28(6):495-512. https://doi.org/10.2165/00002018-200528060-00003
  28. Aronson JK. Medication errors resulting from the confusion of drug names. Expert Opin Drug Saf 2004;3(3):167-72. https://doi.org/10.1517/14740338.3.3.167
  29. Bramley DE. The ability of anaesthetists to identify generic medications from trade names. Anaesth Intensive Care 2009;37(4):624-9. https://doi.org/10.1177/0310057X0903700401
  30. Kim S-J. Patient safety incident reporting status and pharmacist intervention cases (translated title). In: Korean Pharmaceutical Association Patient Safety and Medication Administration Web Symposium, Seoul, Korea, September 24, 2022.
  31. Lee JH, Cho CA, Lee YJ, et al. Proposals for nomenclature of generic drugs to prevent medication errors. J Kor Soc Health-Syst Pharm 2008;25(2):159-68.
  32. Kim JE, Lim SC. A study on correlations between medication error and prescription by trade name. Yakhak Hoeji 2019;63(4):238-46. https://doi.org/10.17480/psk.2019.63.4.238
  33. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis. Hypertension 2010;55(2):399-407. https://doi.org/10.1161/HYPERTENSIONAHA.109.139816
  34. Pappa E, Rizos CV, Filippatos TD, Elisaf MS. Emerging fixed-dose combination treatments for hyperlipidemia. J Cardiovasc Pharmacol Ther 2019;24(4):315-22. https://doi.org/10.1177/1074248419838506
  35. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: A meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich) 2011;13(12):898-909. https://doi.org/10.1111/j.1751-7176.2011.00550.x
  36. Lee Y, Shin J, Kim Y, Kim D-S. Consumption of single products versus fixed-dose combination medicines for hypertension and hyperlipidemia during 2015-2019 in South Korea. PLOS ONE 2021;16(12):e0259467.
  37. Label: Zetia-ezetimibe tablet. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=174e45e0-45bb-48b7-9e60-8f6cfc1d22bb. Accessed September 11, 2023.
  38. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/ AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation 2019;139(25):e1082-143. https://doi.org/10.1161/CIR.0000000000000698
  39. Best practices in developing proprietary names for human prescription drug products; guidance for industry. Silver Spring, MD: U.S. Food and Drug Administration, 2020.
  40. Are national efforts to reduce drug name confusion paying off? ISMP Medication Safety Alert. 2018 November 29:1-6.
  41. Lee SJ, Moon HJ, Kim YS, et al. Drug product name assignment casebook (translated title). 4th ed. Cheongju, Korea: Ministry of Food and Drug Safety, 2022.
  42. INN and Classification of Medical Products. Guidance on the use of international nonproprietary names (INNs) for pharmaceutical substances. Switzerland: World Health Organization (WHO); 2017. Available from: https://www.who.int/publications/m/item/guidanceon-the-use-of-inns. Accessed September 11, 2023.
  43. Garcia BH, Elenjord R, Bjornstad C, Halvorsen KH, Hortemo S, Madsen S. Safety and efficiency of a new generic package labelling: A before and after study in a simulated setting. BMJ Qual Saf 2017;26(10):817-23. https://doi.org/10.1136/bmjqs-2016-006422
  44. Kuperman GJ, Bobb A, Payne TH, et al. Medication-related clinical decision support in computerized provider order entry systems: A review. J Am Med Inform Assoc 2007;14(1):29-40. https://doi.org/10.1197/jamia.M2170